cacy of sevelamer in lowering serum phosphorus in heride in hemodialysis patients: A comparison with calcium acemodialysis patients.
Patients modialysis patients.
The study included male and female hemodialysis paMethods. Administration of phosphate binders was discontients aged 18 years or older who were treated for at tinued during a two-week washout period. The patients were then randomized to receive sevelamer or calcium acetate. The least three months with hemodialysis three times per laboratory tests were performed monthly for 34 weeks.
week. Inclusion criteria required calcium-based phos-
Results. There was a statistically significant decrease of sephate binders and vitamin D therapy at stable doses for rum phosphorus in both sevelamer and calcium acetate treatat least one month. Furthermore, subjects were excluded ments. In addition, sevelamer improved the lipid profile. from participation if they had any unstable medical conConclusion. This study confirms that sevelamer is effective at lowering serum phosphorus in hemodialysis patients and dition, including poorly controlled diabetes mellitus, hythat it has several striking properties that could be beneficial pertension, or any gastrointestinal abnormality.
in atherosclerosis in dialysis patients.
Study design
Patients were chosen and administration of calciumSecondary hyperparathyroidism and hyperphosphatecontaining phosphate binder was discontinued during mia are common complications in end-stage renal disa two-week washout period. Patients who developed a ease. Treatment usually includes dietary restriction of serum phosphorus level greater than 6 mg/dL during this phosphorus, use of carbonate or acetate salts of calcium, washout were eligible for the study. After the two-week and often, the administration of vitamin D metabolites washout phase, subjects were randomized to receive sev- [1, 2, 3] . Calcium salts have become the treatment choice elamer hydrochloride or calcium acetate. Sevelamer was for hyperphosphatemia, although the provision of calsupplied in a capsule containing 403 mg (Renagel), cium can lead to hypercalcemia and increase the risk of while the calcium acetate was supplied as Royen, conmetastatic calcification, particularly in those patients on taining 500 mg calcium acetate. The beginning medicacalcitriol therapy and patients with low bone turnover tion dose was determined by the initial level of phosphorates [1, [3] [4] [5] .
rus and ranged from 2 to 4 capsules three times a day Sevelamer hydrochloride is a recently approved calciwith meals for sevelamer, to 1 to 4 tablets three times um-and aluminum-free phosphate binder. In previous per day with meals for calcium acetate [4, 7] . Sevelamer studies it effectively controlled serum phosphate in heand calcium acetate doses could be increased by one modialysis patients without developing hypercalcemia [6] .
capsule or tablet per meal (three capsules or tablets A randomized study comparing sevelamer and calper day) every four weeks. Serum levels of phosphorus, cium acetate was therefore performed to assess the efficalcium, alkaline phosphatase, parathyroid hormone (PTH), total cholesterol, HDL-cholesterol, LDL-choles- ing calcium acetate treatment. The incidence of diarrhea, constipation, and other minimal adverse events was not statistically different between groups (P ϭ 0.2). In the 30, and 34 during the treatment period. Laboratory tests sevelamer group, there was one patient with a gastric were drawn before the mid-week dialysis session.
bezoar who dropped out of the study.
Statistical analysis Dosage and dietary intake Continuous variables were expressed as mean values Ϯ
For sevelamer, the mean dose given was 4.09 g/day, SD. Baseline characteristics were compared between the and for calcium acetate, the mean dose given was 3.9 g/ two groups of patients using a Fisher exact test for cateday. Dietary intake of calcium, phosphorus, and vitamin gorical variables and a Wilcoxon signed rank test for D metabolites remained relatively stable throughout the continuous variables. The effect of treatment was anastudy and was equivalent between groups. lyzed by measuring the change from the end of the washSerum phosphorus, calcium, alkaline phosphatase, and out period to the determination of the treatment period intact parathyroid hormone by a paired t test. An analysis of variance model was used to assess differences between treatment groups. All Figure 1 shows the changes in serum calcium, serum statistical analyses were two-tailed with a P value of 0.05 phosphorus, and serum calcium x phosphorus product required for significance and conducted using a SPSS.10 in both the calcium and sevelamer groups. The mean software package (SPSS, Inc., Chicago, IL, USA) for serum phosphorus baseline concentration was not statisWindows (Microsoft Corporation, Redmond, WA, USA), tically significant before treatment with sevelamer and and were restricted to subjects who completed the study calcium acetate (8.09 Ϯ 1.6 mg/dL vs. 7.5 Ϯ 1.5 mg/dL; (N ϭ 40, 78%). P ϭ 0.5). There was a statistically significant decrease with both treatments that ranged from 8.09 Ϯ 1.6 mg/dL to 5.8 Ϯ 1.01 mg/dL; P ϭ 0.001 for the sevelamer group, RESULTS and from 7.5 Ϯ 1.6 mg/dL to 5.9 Ϯ 1.5 mg/dL; P ϭ Patients 0.005 for the acetate group. The mean change in serum Sixty-one patients entered the screening period; after phosphorus from baseline to the end of treatment was a washout period, 51 met the study criteria and were similar between treatments: Ϫ2.29 Ϯ 0.05 mg/dL (28.3%) randomized. Forty patients completed the study. Reawith sevelamer and Ϫ1.6 Ϯ 0.1 mg/dL (21.3%) with sons for withdrawal from the study were: four deaths, calcium acetate. There was not a statistically significant two kidney transplants, one adverse event (gastric beincrease of serum calcium in either the sevelamer or zoar), and four cases of lack of compliance. Table 1 calcium acetate therapy (Fig. 1) . At least one instance shows the baseline patients' characteristic. Sevelamer of hypercalcemia, defined as a serum calcium greater was well tolerated and the occurrence of side effects was than 11 mg/dL, occurred in 7.1% (N ϭ 9) of patients similar for each treatment. Dyspepsia occurred during with sevelamer treatment, and in 8.9% (N ϭ 15) of patients with calcium acetate treatment (P ϭ 0.2). Alsevelamer treatment in 38% of patients versus 36% dur-
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cium acetate can lead to hypercalcemia in some patients [1, 3, 5, 14, 15] .
We explored the use of a recently approved calciumand aluminum-free phosphate binder to lower serum phosphorus levels in hemodialysis patients and compared it with a standard therapy on a similar population.
This long-term study confirms previous reports, in which sevelamer is effective at lowering serum phosphorus in hemodialysis patients [4, 7, [16] [17] [18] [19] . Serum phosphorus was significantly reduced by both sevelamer and calcium acetate treatments, with a corresponding reduction in the calcium x phosphorus product. This beneficial effect was sustained over time. The serum phosphorus that observed in other clinical trials. The intact PTH decreased significantly in both sevelamer and calcium acetate treatments, but it did not achieve the normal range in dialysis patients at the end of the study. Perhaps though the mean baseline calcium x phosphorus product the reasons for not achieving optimal levels of both sewas higher before treatment with sevelamer than calcium rum phosphorus and intact PTH were that the dose of acetate (79. sevelamer was sub-optimal (the mean dose given was P ϭ 0.7), the mean change from baseline to the end of 4.09 g/day). The limitation in our patients was the need treatment was similar between treatments (Ϫ20.6 mg for taking a high number of capsules. Recently, the suitwith sevelamer and (Ϫ15.4 mg 2 /dL 2 ) with calcium aceability of sevelamer has been improved with new 800 mg tate. Intact PTH levels also decreased with both treattablets. ments, from 479 Ϯ 288 pg/mL to 330 Ϯ 205 pg/mL; P ϭ Serum calcium was slightly, but not significantly, in-0.04 in the sevelamer group, and from 501 Ϯ 303 pg/mL creased in sevelamer treatment. Because sevelamer deto 346 Ϯ 250 pg/mL; P ϭ 0.02 in the calcium acetate creases serum phosphorus with the ability to avoid hygroup. Serum alkaline phosphatase did not increase sigpercalcemia, we found a subsequent reduction in calcium nificantly with sevelamer treatment (230 Ϯ 78 UI/L to x phosphorus product. This is probably the most impor-243 Ϯ 65 UI/L; P ϭ 0.3) and did not change significantly tant sevelamer benefit. Block et al [20] recently pointed with calcium acetate therapy (227 Ϯ 93 UI/L to 226 Ϯ out an increase in the relative risk of death with higher 120 UI/L; P ϭ 0.9). levels of calcium x phosphorus product. Other authors have also hypothesized that higher levels of the calcium x Serum lipids phosphorus product might promote vascular calcification Figure 2 shows the changes on the lipid profile. For and lead to a decrease in survival related to cardiovascuthe sevelamer treatment group, the mean change in the lar disease [16] . Coronary-artery calcification is common total cholesterol was Ϫ30.5 Ϯ 13.1 mg/dL (Ϫ16.5%), and progressive in young adults who are undergoing LDL-cholesterol was Ϫ32.8 Ϯ 14.5 mg/dL (Ϫ29.9%), dialysis [21, 22] . There is evidence that an effective phosand HDL-cholesterol was 8.2 Ϯ 4.6 mg/dL (19.5%). All phate lowering with sevelamer is associated with less values were statistically significant at P Ͻ 0.05. For the coronary and aortic calcification [23] . calcium acetate treatment group, the mean levels of total
The mild increase in serum alkaline phosphatase durcholesterol, LDL-cholesterol and HDL-cholesterol ing sevelamer treatment was most likely related to its were not significantly changed.
effects on bile acid metabolism [7, 16] . In both treatments, other laboratory values such as triglycerides, serum albumin, total protein, liver enzymes, CONCLUSION and bilirubin were not significantly changed.
Sevelamer treatment reduced both serum total cholesterol and LDL-cholesterol. The 29% reduction in LDL-DISCUSSION cholesterol by sevelamer treatment is similar to the reThe efficacy of currently available calcium-or alumiduction obtained by cholesterol-lowering agents [24, 25] . num-containing phosphate binders is constrained by the Nevertheless, alternatives to HMG-CoA reductase inside effects associated with the absorption of calcium hibitors may be advisable, given the increased risk of and aluminum. Aluminum absorption can lead to toxicity drug-related side effects in patients with chronic renal failure [18] . In addition, sevelamer treatment signifiin some patients [8] [9] [10] [11] [12] [13] , and calcium carbonate or cal-
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9. Kaye M: Oral aluminium toxicity in a nondialized patient with cantly increases HDL-cholesterol [16] , or has no effect renal failure. Clin Nephrol 20:208-211, 1983 at all [7, 18, 19] 
